Caris Life Sciences (NasdaqGS:CAI) published a pivotal study on its Caris Lookback Program confirming its effectiveness in finding patients eligible for newly approved targeted therapies. The company ...

In a recent article published in BMC Medical Genomics, researchers recruited a cohort of 25 Chinese genodermatoses patients to examine the genetic etiology by whole-exome sequencing (WES). They ...

Claritas Genomics, Inc., announced the launch of its Claritas Clinical Exome, at the Annual Meeting of the American Society of Human Genetics running 10/6 – 10/10 in Baltimore, MD. This novel ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side analysts ...

A single genetic test could potentially replace the current two-step approach to diagnosing rare developmental disorders in children. This shift could enable earlier diagnoses for families and save ...

Please provide your email address to receive an email when new articles are posted on . More than half of individuals appeared unaware they carried predisposition genes. Nearly 40% of carriers would ...

Although whole-exome sequencing (WES) has its limitations, particularly with respect to secondary or incidental findings, it may still shine in routine clinical care, particularly if testing is ...

We evaluated the feasibility of high-resolution noninvasive prenatal screening in 51 pregnancies that were representative of the pregnant population receiving care at the recruitment hospital (Tables ...

The optimising EXome PREnatal Sequencing Services (EXPRESS) policy report outlines actions to strengthen clinical implementation of, and further research on, prenatal exome sequencing services in the ...

GeneDx raised full year 2025 total revenue guidance to $425 million to $428 million. Exome and genome revenue guidance was increased to $358 million to $361 million, reflecting 53% to 55% growth for ...